Dynavax Technologies reported $1.68M in Interest Expense on Debt for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Adma Biologics ADMA:US $ 3.39M 0.07M
Agenus AGEN:US $ 15.2M 1.37M
Amgen AMGN:US $ 328M 33M
Biogen BIIB:US $ 65.8M 0.3M
Biomarin Pharmaceutical BMRN:US $ 3.86M 0.05M
Bristol Myers Squibb BMY:US $ 313M 13M
Dynavax Technologies DVAX:US $ 1.68M 0M
Gilead Sciences GILD:US $ 242M 4M
Idera Pharmaceuticals IDRA:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 7.23M 0.3M
Neurocrine Biosciences NBIX:US $ 2.2M 0.4M
Novartis NOVN:VX 202M 1000K
Pfizer PFE:US $ 293M 29M
Regeneron Pharmaceuticals REGN:US $ 13.1M 0.5M
Sarepta Therapeutics SRPT:US $ 16.03M 0.23M
Tg Therapeutics TGTX:US $ 2.66M 1.58M
Vertex Pharmaceuticals VRTX:US $ 14.6M 0.3M